Search Results
604 results
Your search is now limited to «Drugs» expert search.
GlobeNewswire 01/22/2019 07:45
The study drug (DM199 or placebo) will be administered as an intravenous (“IV”) infusion within 24 hours of stroke symptom onset, followed by SC injections on day 1 and every 3 days for 21 days.
More from GlobeNewswire:
Cardiac Rhythm News 01/22/2019 06:53
One of the most common cardiac arrhythmias in the world, atrial fibrillation, can affect how efficiently the heart pumps blood through the body, causing symptoms such as dizziness, shortness of breath or lightheadedness.
More from Cardiac Rhythm News:
Tolvaptan, a vasopressin antagonist, could be adopted in heart failure therapy as it reduces pre- and afterload by decreasing systolic blood pressure and blood volume.
More from International Journal of COPD:
MedPageToday.com 01/21/2019 15:00
Perry: I find that having cared for a few patients with pulmonary hypertension, I find that generally folks with left side heart failure or chronic obstructive pulmonary disease, that their pulmonary hypertension is usually pretty mild.
More from MedPageToday.com:
American Diabetes Journals 01/21/2019 14:50
We examined the placebo arm of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) to determine whether the effects of drop-in open-label dapagliflozin on MACE, ACM, and estimated glomerular filtration rate (eGFR) were consistent with the SGLT2i class as a whole.
Health Imaging 01/21/2019 14:23
An additional 2.5 percent were linked to “other” cardiac causes, like anomalous coronary arteries, tamponade and coronary heart disease.
More from Health Imaging:
Healio News 01/21/2019 12:09
FDA panel asserts febuxostat benefits outweigh CV risks, short sleep time increases atherosclerosis risk.
More from Healio News:
As more physicians turn to cardiac ablation to treat AFib, Abbott's goal is to equip them with the most advanced ablation catheters combined with the most advanced cardiac mapping on the market.
More from Healthcare Sales & Marketing Network:
FeedNavigator 01/20/2019 09:12
Patients with type 2 diabetes mellitus or cardiovascular disease were included.
More from FeedNavigator:
BIOENGINEER.ORG 01/18/2019 17:48
Credit: Furukawa Lab/CSHL Cold Spring Harbor, NY — The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists at Cold Spring Harbor Laboratory have revealed a mechanism that […]
More from BIOENGINEER.ORG:
Technology Org 01/18/2019 15:49
Hundreds of thousands of deaths every year can be traced back to hypertension, better known simply as high blood pressure.
More from Technology Org:
Motley Fool 01/18/2019 13:42
Used in conjunction with the ECG app, this technology underpins the Watch's ability to test the user's heart rhythm by holding the digital crown button down for 30 seconds, classifying the heart rhythm as normal, AFib, or inconclusive.
More from Motley Fool:
USAToday (United States) 01/18/2019 12:15
High blood pressure can contribute to heart failure, heart attack, stroke, and chronic kidney disease.
More from USAToday (United States):
ClinicalTrials.gov 01/18/2019 12:00
Condition : Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Intervention : Drug: macitentan 10 mg Sponsors : Actelion; EPS Corporation; Imepro Inc.; General Laboratory, BML, Inc.; Mitsubishi Logistics Corporation Recruiting.
More from ClinicalTrials.gov:
Top Class Actions 01/18/2019 07:00
Recent class action lawsuits and investigations allege that valsartan, a blood pressure drug meant to treat hypertension, may cause liver damage or cancer due to a lack of quality control at its production site factory.
More from Top Class Actions:
Medindia.com 01/18/2019 01:52
Immune system cells could be the key to tackling hypertension (high blood pressure), said researchers.
More from Medindia.com:
Lancet 01/17/2019 23:02
The FLAME trial was done in nine centres in France, in 118 patients with ischaemic stroke and unilateral weakness.
More from Lancet:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications